Search Results
Charles Rudin, MD, PhD, shares the take home message regarding Keynote-604 for lung cancer treatment
Charles Rudin, MD, PhD, shares outcomes of the Keynote 604 study to investigating Keytruda and chemo
Charles Rudin, MD, PhD, discusses the Keynote-604 study and the role of Keytruda in ES-SCLC
Dr. Rudin on the Design of the KEYNOTE-604 Trial in ES-SCLC
Researcher comment: The KEYNOTE-604 trial | Charles Rudin
KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy for extensive-sta...
Dr. Charles Rudin: Research Funding
Dr. Charles Rudin: Immunotherapy for Small Cell Lung Cancer
Small Cell Lung Cancer: Future Directions in Care
In What Clinical Setting Should Immunotherapies Be Developed?
Chemoimmunotherapy for ES SCLC: CASPIAN Trial
